IL153264A0 - A compound having corticotropin releasing factor receptor ligand activity and pharmaceutical compositions containing the same - Google Patents
A compound having corticotropin releasing factor receptor ligand activity and pharmaceutical compositions containing the sameInfo
- Publication number
- IL153264A0 IL153264A0 IL15326401A IL15326401A IL153264A0 IL 153264 A0 IL153264 A0 IL 153264A0 IL 15326401 A IL15326401 A IL 15326401A IL 15326401 A IL15326401 A IL 15326401A IL 153264 A0 IL153264 A0 IL 153264A0
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutical compositions
- same
- compositions containing
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21939100P | 2000-07-19 | 2000-07-19 | |
| PCT/US2001/022808 WO2002005749A2 (en) | 2000-07-19 | 2001-07-19 | Crf2 ligands in combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL153264A0 true IL153264A0 (en) | 2003-07-06 |
Family
ID=22819077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15326401A IL153264A0 (en) | 2000-07-19 | 2001-07-19 | A compound having corticotropin releasing factor receptor ligand activity and pharmaceutical compositions containing the same |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20020035083A1 (xx) |
| EP (1) | EP1383460A2 (xx) |
| JP (1) | JP2004513880A (xx) |
| KR (1) | KR20040014926A (xx) |
| CN (1) | CN1501976A (xx) |
| AU (1) | AU2001280632A1 (xx) |
| BG (1) | BG107364A (xx) |
| BR (1) | BR0111937A (xx) |
| CA (1) | CA2416986A1 (xx) |
| CZ (1) | CZ2003159A3 (xx) |
| EE (1) | EE200300025A (xx) |
| HU (1) | HUP0301833A3 (xx) |
| IL (1) | IL153264A0 (xx) |
| IS (1) | IS6673A (xx) |
| MX (1) | MXPA02012721A (xx) |
| NO (1) | NO20030214D0 (xx) |
| PL (1) | PL365955A1 (xx) |
| RU (1) | RU2003104509A (xx) |
| WO (1) | WO2002005749A2 (xx) |
| ZA (1) | ZA200300088B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| WO2007100775A2 (en) * | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US9555032B2 (en) | 2007-06-13 | 2017-01-31 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| CN104231059B (zh) * | 2013-06-19 | 2016-12-28 | 深圳翰宇药业股份有限公司 | 一种多肽及其制备方法和用途 |
| JP2019533021A (ja) * | 2016-10-20 | 2019-11-14 | コーティーン インコーポレイテッド | 不適応のストレス応答に寄与する疾患を処置する方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) * | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5063245A (en) * | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
| AU703140B2 (en) * | 1994-06-14 | 1999-03-18 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| US5663292A (en) * | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US6214797B1 (en) * | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
| US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| US5861398A (en) * | 1996-08-26 | 1999-01-19 | Alanex Corporation | Benzoperimidine-carboxylic acids and derivatives thereof |
| GB9717087D0 (en) * | 1997-08-12 | 1997-10-15 | Ciba Geigy Ag | Improvements in or relating to organic compounds |
-
2001
- 2001-07-19 AU AU2001280632A patent/AU2001280632A1/en not_active Abandoned
- 2001-07-19 JP JP2002511684A patent/JP2004513880A/ja active Pending
- 2001-07-19 IL IL15326401A patent/IL153264A0/xx unknown
- 2001-07-19 MX MXPA02012721A patent/MXPA02012721A/es unknown
- 2001-07-19 HU HU0301833A patent/HUP0301833A3/hu unknown
- 2001-07-19 CA CA002416986A patent/CA2416986A1/en not_active Abandoned
- 2001-07-19 RU RU2003104509/14A patent/RU2003104509A/ru not_active Application Discontinuation
- 2001-07-19 PL PL01365955A patent/PL365955A1/xx not_active Application Discontinuation
- 2001-07-19 US US09/908,825 patent/US20020035083A1/en not_active Abandoned
- 2001-07-19 EE EEP200300025A patent/EE200300025A/xx unknown
- 2001-07-19 BR BR0111937-0A patent/BR0111937A/pt not_active IP Right Cessation
- 2001-07-19 EP EP01959036A patent/EP1383460A2/en not_active Withdrawn
- 2001-07-19 CZ CZ2003159A patent/CZ2003159A3/cs unknown
- 2001-07-19 CN CNA01814084XA patent/CN1501976A/zh active Pending
- 2001-07-19 WO PCT/US2001/022808 patent/WO2002005749A2/en not_active Application Discontinuation
- 2001-07-19 KR KR10-2003-7000716A patent/KR20040014926A/ko not_active Application Discontinuation
-
2002
- 2002-12-09 BG BG107364A patent/BG107364A/bg unknown
-
2003
- 2003-01-03 ZA ZA200300088A patent/ZA200300088B/en unknown
- 2003-01-08 IS IS6673A patent/IS6673A/is unknown
- 2003-01-16 NO NO20030214A patent/NO20030214D0/no not_active Application Discontinuation
-
2004
- 2004-08-26 US US10/926,558 patent/US20050059627A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001280632A1 (en) | 2002-01-30 |
| KR20040014926A (ko) | 2004-02-18 |
| WO2002005749A3 (en) | 2003-11-06 |
| CZ2003159A3 (cs) | 2004-02-18 |
| MXPA02012721A (es) | 2003-04-25 |
| HUP0301833A2 (hu) | 2003-09-29 |
| JP2004513880A (ja) | 2004-05-13 |
| BR0111937A (pt) | 2005-04-12 |
| EE200300025A (et) | 2005-04-15 |
| RU2003104509A (ru) | 2004-08-27 |
| US20050059627A1 (en) | 2005-03-17 |
| EP1383460A2 (en) | 2004-01-28 |
| NO20030214L (no) | 2003-01-16 |
| HUP0301833A3 (en) | 2005-12-28 |
| WO2002005749A2 (en) | 2002-01-24 |
| PL365955A1 (en) | 2005-01-24 |
| BG107364A (bg) | 2003-07-31 |
| CN1501976A (zh) | 2004-06-02 |
| NO20030214D0 (no) | 2003-01-16 |
| IS6673A (is) | 2003-01-08 |
| US20020035083A1 (en) | 2002-03-21 |
| ZA200300088B (en) | 2005-05-09 |
| CA2416986A1 (en) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301777A3 (en) | Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use | |
| IL148489A0 (en) | Quinazoline compounds and pharmaceutical compositions containing them | |
| HUP0204272A3 (en) | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use | |
| IL152024A0 (en) | Pharmaceutical compositions containing thyroid hormone and processes for the manufacture thereof | |
| HUP0203378A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
| HUP0203939A3 (en) | Pharmaceutical compounds and compositions containing them and their use | |
| HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
| PT1213020E (pt) | Compostos e composições farmacêuticas com actividade supressora do apetite | |
| HU0004123D0 (en) | New compounds with pharmaceutical activity | |
| IL155196A0 (en) | Benzamide derivatives and pharmaceutical compositions containing the same | |
| IL144879A0 (en) | Hererocyclic biphenyl compounds and pharmaceutical compositions containing the same | |
| HUP0100266A3 (en) | 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing the compounds and their preparations | |
| HUP0201818A3 (en) | 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same | |
| IL150383A0 (en) | Glyburide and pharmaceutical compositions containing the same | |
| IL143841A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
| IL139865A0 (en) | A liver selective glucocorticoid antagonist and pharmaceutical compositions containing the same | |
| HUP0201952A2 (en) | Androgen compounds and pharmaceutical compounds containing the same | |
| IL134536A0 (en) | Compounds possessing neuronal activity and pharmaceutical compositions containing the same | |
| PL352159A1 (en) | Pharmaceutical compositions containing antibody against the fas | |
| HUP0200747A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
| HUP0200055A3 (en) | 16-hydroxyestrienes and pharmaceutical compositions containing the same | |
| HUP0200121A3 (en) | Calcilytic compounds, pharmaceutical compositions containing them and their use | |
| IL153264A0 (en) | A compound having corticotropin releasing factor receptor ligand activity and pharmaceutical compositions containing the same | |
| AU4875301A (en) | Nitrogenous compounds and antiviral drugs containing the same | |
| GB9803521D0 (en) | New compounds and pharmaceutical compositions thereof |